MeSH tree: C08.381.540.140.500
A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study ...
Feb 13, 2024
0
49
A new case report titled "Lazarus effect in a patient initially empirically treated with osimertinib for EGFR L858R mutant non-small cell lung cancer with leptomeningeal disease: a case report" has been published in Oncotarget.
Jan 24, 2024
0
49
A new study has found that patients with non-small cell lung cancer (NSCLC) treated with a combination of low-dose radiation and immunotherapy had higher progression-free survival compared to patients who received immunotherapy ...
Jan 16, 2024
0
45
Lung cancer accounts for nearly 20% of annual cancer-related deaths worldwide. According to 2022 statistics from the Swiss Cancer League, nearly 5,000 new cases of lung cancer are reported in Switzerland each year. Over the ...
Jan 8, 2024
0
30
A new study led by Yale Cancer Center researchers at Yale School of Medicine has revealed a significant increase in patients starting immunotherapy within one month of death. Using a national clinical database, the researchers ...
Jan 4, 2024
0
75
A novel PET imaging tracer has been proven to safely and effectively detect a common cancer gene mutation that is an important molecular marker for tumor-targeted therapy. By identifying this mutation early, physicians can ...
Dec 20, 2023
0
69
New research in the December 2023 issue of Journal of the National Comprehensive Cancer Network finds that patients treated with first-line immunotherapy for advanced non-small cell lung cancer (NSCLC) showed similar results ...
Dec 11, 2023
0
26
Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).
Dec 6, 2023
0
110
Researchers at Dana-Farber Cancer Institute have developed a promising new drug candidate, EAI-432, to treat non-small cell lung cancers (NSCLC)driven by mutations in the EGFR gene, particularly the L858R mutation which is ...
Nov 30, 2023
0
50
For patients with advanced or metastatic non-small cell lung cancer (NSCLC) and limited performance status, an immune checkpoint inhibitor drug called durvalumab is safe and may benefit overall survival, according to a new ...
Nov 21, 2023
0
57
